Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Kantonsspital Aarau AG

ClinicalTrials.gov lists Kantonsspital Aarau AG as lead sponsor of 27 trials. It has 3 approved assets.

CH Hospital Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

6 0 2005 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Kantonsspital Aarau AG: 27 lead-sponsored trials and 2 legal-entity registrations.

Get the Kantonsspital Aarau AG report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (92)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pelvic Organ Prolapse 4
Brain Neoplasms 3
Head and Neck Neoplasms 3
Heat Stress Disorders 3
Hyperthermia 3

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 4
2025 5
2024 2
2023 3
2022 4
2021 4
2020 2
2019 2
2018 5
2017 3

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Approved assets (3)

Shown in this order: max phase first.

Approved assets
Drug Trials
Lactose 1
Mannose 1
Ruxolitinib 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
57% hit target (n=7) 71% on time (n=7)

Journals published in (88)

Shown in this order: most published in first.

Journals published in
Journal Publications
Swiss medical weekly 6
Annals of surgery 4
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 4
European journal of trauma and emergency surgery : official publication of the European Trauma Society 4
Journal of vascular surgery 4

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
3 0 2018-10-02

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
Kantonsspital Aarau AG Aarau, CH EMA

Organization relationships (21)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Insel Gruppe AG, University Hospital Bern Co sponsors trial with 6
Centre Hospitalier Universitaire Vaudois Co sponsors trial with 3
University Hospital, Basel, Switzerland Co sponsors trial with 2
Ostschweizer Kinderspital Co sponsors trial with 2
University Hospital, Geneva Co sponsors trial with 2

Latest dated events (65)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-06-24 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-27 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (38)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
AMPH Trial collaborator Named in trial inclusion criteria
C12orf57 Trial collaborator Named in trial inclusion criteria
CNTNAP1 Trial collaborator Named in trial inclusion criteria
CNTNAP2 Trial collaborator Named in trial inclusion criteria
DPYSL5 Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.